Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Fineline Cube Jun 18, 2026
Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production

Fineline Cube Jul 4, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...

Company Drug

Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention

Fineline Cube Jul 4, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...

Company

Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park

Fineline Cube Jul 4, 2022

Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Fineline Cube Jul 4, 2022

The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...

Company Deals

HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs

Fineline Cube Jul 4, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Policy / Regulatory

NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...

Company Drug

Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials

Fineline Cube Jul 1, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...

Company Drug

Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...

Company R&D

Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection

Fineline Cube Jul 1, 2022

Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...

Company Deals

Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing

Fineline Cube Jul 1, 2022

China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...

Policy / Regulatory

NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...

Company Drug

BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study

Fineline Cube Jul 1, 2022

BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...

Policy / Regulatory

NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Posts pagination

1 … 674 675 676 … 685

Recent updates

  • Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant
  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.